Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromes
Authors:
Open Access
- 16 February 2017
- journal article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 102 (6) , e216-e218
Abstract
Post-transplant relapse remains a major cause of treatment failure in patients with myeloid malignancies such as myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Despite interventions such as withdrawal of immunosuppression, administration of chemotherapy, donor lymphocyte infusion (Keywords
This publication has 14 references indexed in Scilit:
- Factors Determining Responses to Azacitidine in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Early Post-Transplantation Relapse: A Prospective TrialTransplantation and Cellular Therapy, 2017
- Decitabine As Salvage Therapy for Relapse of AML and MDS after Allogeneic Stem Cell Transplantation - a Retrospective Multicenter Analysis on Behalf of the German Cooperative Transplant Study GroupBlood, 2016
- Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemiaHaematologica, 2016
- Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemiaNature, 2014
- TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patientsBlood, 2014
- Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell TransplantationJournal of Clinical Oncology, 2014
- Clinical and biological implications of driver mutations in myelodysplastic syndromesBlood, 2013
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid LeukemiaNew England Journal of Medicine, 2013
- Maintenance therapy with low‐dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndromeCancer, 2010
- Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2007